Harvard Bioscience, Inc.
General ticker "HBIO" information:
- Sector: Health Care
- Industry: Life Sciences Tools & Services
- Capitalization: $96.3M
Harvard Bioscience, Inc. does not follow the US Stock Market performance with the rate: -28.8%.
Estimated limits based on current volatility of 3.3%: low 2.02$, high 2.16$
Factors to consider:
- China accounted for 16.5% of revenue in the fiscal year ended 2023-12-31
- US accounted for 42.9% of revenue in the fiscal year ended 2023-12-31
- Current price 34.3% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [3.21$, 6.07$]
- 2024-12-30 to 2025-12-30 estimated range: [3.96$, 7.09$]
Financial Metrics affecting the HBIO estimates:
- Positive: 0.10 < Non-GAAP EPS, $ of 0.15
- Negative: Industry operating cash flow per share per price (median), % of 0.50 <= 3.85
- Negative: negative Net income
- Positive: 2.35 < Operating cash flow per share per price, % of 6.84
- Positive: 1.03 < Operating profit margin, % of 1.69
Short-term HBIO quotes
Long-term HBIO plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $118.90MM | $113.33MM | $112.25MM |
| Operating Expenses | $116.84MM | $120.27MM | $110.36MM |
| Operating Income | $2.07MM | $-6.93MM | $1.89MM |
| Non-Operating Income | $-2.21MM | $-2.25MM | $-4.45MM |
| Interest Expense | $1.54MM | $2.25MM | $3.59MM |
| R&D Expense | $10.80MM | $12.33MM | $11.76MM |
| Income(Loss) | $-0.14MM | $-9.18MM | $-2.56MM |
| Taxes | $0.15MM | $0.34MM | $0.86MM |
| Profit(Loss) | $-0.29MM | $-9.52MM | $-3.42MM |
| Stockholders Equity | $83.40MM | $72.22MM | $73.07MM |
| Inventory | $27.59MM | $26.44MM | $24.72MM |
| Assets | $162.34MM | $145.36MM | $137.37MM |
| Operating Cash Flow | $1.26MM | $1.15MM | $14.03MM |
| Capital expenditure | $1.34MM | $1.59MM | $2.31MM |
| Investing Cash Flow | $-1.34MM | $-1.59MM | $-1.80MM |
| Financing Cash Flow | $-0.25MM | $-2.84MM | $-12.13MM |
| Earnings Per Share* | $-0.01 | $-0.23 | $-0.08 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.